APA (7th ed.) Citation

MS, D., YH, F., SW, C., N, M., T, Y., ST, C., . . . MF, H. (2021). Analysis of the pan-Asian subgroup of patients in the NALA Trial: A randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens. Breast cancer research and treatment, 189(3), 665. https://doi.org/10.1007/s10549-021-06313-5

Chicago Style (17th ed.) Citation

MS, Dai, et al. "Analysis of the Pan-Asian Subgroup of Patients in the NALA Trial: A Randomized Phase III NALA Trial Comparing Neratinib+capecitabine (N+C) Vs Lapatinib+capecitabine (L+C) in Patients with HER2+metastatic Breast Cancer (mBC) Previously Treated with Two or More HER2-directed Regimens." Breast Cancer Research and Treatment 189, no. 3 (2021): 665. https://doi.org/10.1007/s10549-021-06313-5.

MLA (9th ed.) Citation

MS, Dai, et al. "Analysis of the Pan-Asian Subgroup of Patients in the NALA Trial: A Randomized Phase III NALA Trial Comparing Neratinib+capecitabine (N+C) Vs Lapatinib+capecitabine (L+C) in Patients with HER2+metastatic Breast Cancer (mBC) Previously Treated with Two or More HER2-directed Regimens." Breast Cancer Research and Treatment, vol. 189, no. 3, 2021, p. 665, https://doi.org/10.1007/s10549-021-06313-5.